

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.

A medical syringe is seen with the Moderna company logo displayed on a screen in the background on June 12, 2020. (Photo: Jakub Porzycki/NurPhoto via Getty Images)
With Moderna already under fire globally for prioritizing the vaccination demands of rich countries in the ongoing fight against Covid-19, the chairman and co-founder reiterated Monday that the American company will not share its vaccine recipe.
In an interview with The Associated Press, Moderna's Noubar Afeyan claimed that appeals from the World Health Organization (WHO) and others to share the recipe assumed "that we couldn't get enough capacity, but in fact we know we can."
"Within the next six to nine months, the most reliable way to make high-quality vaccines and in an efficient way is going to be if we make them," Afeyan said, noting that Moderna "went from having zero production to having one billion doses in less than a year" and "we think we will be able to go from one to three billion" next year.
"We think we are doing everything we can to help this pandemic," added Afeyan, who is among the Moderna founders who were named to Forbes' list of the 400 richest people in the United States for the first time last week.
Afeyan also said Moderna--which has received billions of dollars from the U.S. government for development and doses of its messenger RNA (mRNA) vaccine--will continue to not enforce patent infringement during the pandemic, adding that "we didn't have to do that."
"We think that was the right, responsible thing to do," he said of the decision to not legally go after others making Covid-19 vaccines during the crisis. "We want that to be helping the world."
Critics of Moderna and other vaccine makers have argued that Big Pharma can help battle the pandemic by supporting patent waivers and widely sharing necessary information about vaccines and treatments to rapidly scale up production.
Last week, Moderna announced it "will build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year."
As Common Dreams reported, critics warned the move could be nothing more than a "PR gimmick" designed to stall or totally derail discussions about a patent waiver for Covid-19 vaccines and "divert focus" from the WHO's mRNA technology transfer initiative in South Africa.
Moderna also faced criticism after The New York Times reported Saturday that the company "has been supplying its shots almost exclusively to wealthy nations, keeping poorer countries waiting and earning billions in profit."
After noting that "Moderna has shipped a greater share of its doses to wealthy countries than any other vaccine manufacturer, according to Airfinity, a data firm that tracks vaccine shipments," the newspaper provided context about various companies:
About one million doses of Moderna's vaccine have gone to countries that the World Bank classifies as low income. By contrast, 8.4 million Pfizer doses and about 25 million single-shot Johnson & Johnson doses have gone to those countries.
Of the handful of middle-income countries that have reached deals to buy Moderna's shots, most have not yet received any doses, and at least three have had to pay more than the United States or European Union did, according to government officials in those countries...
Unlike Pfizer, Johnson & Johnson, and AstraZeneca, which have diverse rosters of drugs and other products, Moderna sells only the Covid vaccine. The Massachusetts company's future hinges on the commercial success of its vaccine.
Afeyan, in his interview with the AP, pushed back, saying that Moderna supplied a "quite significant" output to poorer nations and is currently working with multiple governments "to help them secure supplies for the express purpose of supplying to low-income countries."
Dr. Tom Frieden, a former head of the U.S. Centers for Disease Control and Prevention, told the Times Moderna is "behaving as if they have absolutely no responsibility beyond maximizing the return on investment."
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
With Moderna already under fire globally for prioritizing the vaccination demands of rich countries in the ongoing fight against Covid-19, the chairman and co-founder reiterated Monday that the American company will not share its vaccine recipe.
In an interview with The Associated Press, Moderna's Noubar Afeyan claimed that appeals from the World Health Organization (WHO) and others to share the recipe assumed "that we couldn't get enough capacity, but in fact we know we can."
"Within the next six to nine months, the most reliable way to make high-quality vaccines and in an efficient way is going to be if we make them," Afeyan said, noting that Moderna "went from having zero production to having one billion doses in less than a year" and "we think we will be able to go from one to three billion" next year.
"We think we are doing everything we can to help this pandemic," added Afeyan, who is among the Moderna founders who were named to Forbes' list of the 400 richest people in the United States for the first time last week.
Afeyan also said Moderna--which has received billions of dollars from the U.S. government for development and doses of its messenger RNA (mRNA) vaccine--will continue to not enforce patent infringement during the pandemic, adding that "we didn't have to do that."
"We think that was the right, responsible thing to do," he said of the decision to not legally go after others making Covid-19 vaccines during the crisis. "We want that to be helping the world."
Critics of Moderna and other vaccine makers have argued that Big Pharma can help battle the pandemic by supporting patent waivers and widely sharing necessary information about vaccines and treatments to rapidly scale up production.
Last week, Moderna announced it "will build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year."
As Common Dreams reported, critics warned the move could be nothing more than a "PR gimmick" designed to stall or totally derail discussions about a patent waiver for Covid-19 vaccines and "divert focus" from the WHO's mRNA technology transfer initiative in South Africa.
Moderna also faced criticism after The New York Times reported Saturday that the company "has been supplying its shots almost exclusively to wealthy nations, keeping poorer countries waiting and earning billions in profit."
After noting that "Moderna has shipped a greater share of its doses to wealthy countries than any other vaccine manufacturer, according to Airfinity, a data firm that tracks vaccine shipments," the newspaper provided context about various companies:
About one million doses of Moderna's vaccine have gone to countries that the World Bank classifies as low income. By contrast, 8.4 million Pfizer doses and about 25 million single-shot Johnson & Johnson doses have gone to those countries.
Of the handful of middle-income countries that have reached deals to buy Moderna's shots, most have not yet received any doses, and at least three have had to pay more than the United States or European Union did, according to government officials in those countries...
Unlike Pfizer, Johnson & Johnson, and AstraZeneca, which have diverse rosters of drugs and other products, Moderna sells only the Covid vaccine. The Massachusetts company's future hinges on the commercial success of its vaccine.
Afeyan, in his interview with the AP, pushed back, saying that Moderna supplied a "quite significant" output to poorer nations and is currently working with multiple governments "to help them secure supplies for the express purpose of supplying to low-income countries."
Dr. Tom Frieden, a former head of the U.S. Centers for Disease Control and Prevention, told the Times Moderna is "behaving as if they have absolutely no responsibility beyond maximizing the return on investment."
With Moderna already under fire globally for prioritizing the vaccination demands of rich countries in the ongoing fight against Covid-19, the chairman and co-founder reiterated Monday that the American company will not share its vaccine recipe.
In an interview with The Associated Press, Moderna's Noubar Afeyan claimed that appeals from the World Health Organization (WHO) and others to share the recipe assumed "that we couldn't get enough capacity, but in fact we know we can."
"Within the next six to nine months, the most reliable way to make high-quality vaccines and in an efficient way is going to be if we make them," Afeyan said, noting that Moderna "went from having zero production to having one billion doses in less than a year" and "we think we will be able to go from one to three billion" next year.
"We think we are doing everything we can to help this pandemic," added Afeyan, who is among the Moderna founders who were named to Forbes' list of the 400 richest people in the United States for the first time last week.
Afeyan also said Moderna--which has received billions of dollars from the U.S. government for development and doses of its messenger RNA (mRNA) vaccine--will continue to not enforce patent infringement during the pandemic, adding that "we didn't have to do that."
"We think that was the right, responsible thing to do," he said of the decision to not legally go after others making Covid-19 vaccines during the crisis. "We want that to be helping the world."
Critics of Moderna and other vaccine makers have argued that Big Pharma can help battle the pandemic by supporting patent waivers and widely sharing necessary information about vaccines and treatments to rapidly scale up production.
Last week, Moderna announced it "will build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year."
As Common Dreams reported, critics warned the move could be nothing more than a "PR gimmick" designed to stall or totally derail discussions about a patent waiver for Covid-19 vaccines and "divert focus" from the WHO's mRNA technology transfer initiative in South Africa.
Moderna also faced criticism after The New York Times reported Saturday that the company "has been supplying its shots almost exclusively to wealthy nations, keeping poorer countries waiting and earning billions in profit."
After noting that "Moderna has shipped a greater share of its doses to wealthy countries than any other vaccine manufacturer, according to Airfinity, a data firm that tracks vaccine shipments," the newspaper provided context about various companies:
About one million doses of Moderna's vaccine have gone to countries that the World Bank classifies as low income. By contrast, 8.4 million Pfizer doses and about 25 million single-shot Johnson & Johnson doses have gone to those countries.
Of the handful of middle-income countries that have reached deals to buy Moderna's shots, most have not yet received any doses, and at least three have had to pay more than the United States or European Union did, according to government officials in those countries...
Unlike Pfizer, Johnson & Johnson, and AstraZeneca, which have diverse rosters of drugs and other products, Moderna sells only the Covid vaccine. The Massachusetts company's future hinges on the commercial success of its vaccine.
Afeyan, in his interview with the AP, pushed back, saying that Moderna supplied a "quite significant" output to poorer nations and is currently working with multiple governments "to help them secure supplies for the express purpose of supplying to low-income countries."
Dr. Tom Frieden, a former head of the U.S. Centers for Disease Control and Prevention, told the Times Moderna is "behaving as if they have absolutely no responsibility beyond maximizing the return on investment."